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S
enator Daniel Patrick Moynihan once famously said that
people are entitled to their own opinions not their own
facts. However, these days it seems that industry or think
tanks can produce literature either in the form of research or
expert opinion and then rely on the media and policymakers to
repeat them to the point that they become well-known facts.
For example, it is “well known” that the cost of creating a new
drug is $802 million dollars.
1 However, fewer people realize
that this cost estimate for drug development is based on a non-
random sample of ten companies for which the data is
proprietary and thus not accessible by independent research-
ers.
2 Furthermore, the research center that issues such
reports is mainly funded by the pharmaceutical industry
which would give most consumers of this research reason to
pause. There are many such examples in the pharmaceutical
policy arena. For example, it is “well known” that if drug prices
were reduced pharmaceutical innovation in the US would be
adversely affected. The domestic policy concern about preserv-
ing innovation has even affected US trade relations-the US
government has insisted on national formulary changes in
Australia and South Korea to ensure sustained innovation.
3,4
However, to our knowledge no study has specifically compared
innovation between pharmaceutical manufacturers in the US
and other countries, nor proven that Australia’s evidence
based formulary, for example, has adversely affected innova-
tion. Repetition and dissemination appear to create “facts.”
In this issue of JGIM, Baker and Fugh-Berman review the
research of Dr. Frank Lichtenberg.
5 Dr. Lichtenberg is an
influential health economist whose research focuses on the
impact of newer drugs on health, productivity, and spending.
His work has been published in a number of peer-reviewed
journals, cited in the lay press and congressional documents,
and has been widely disseminated on the Internet.
6–10 Baker
and Fugh-Berman’s critique pertains to a 2007 study by
Lichtenberg that addresses the question of whether newer
drugs have a greater impact on increasing life expectancy and
decreasing morbidity compared to older drugs (newer vs. older
“vintage” drugs, as Lichtenberg terms them). Their Perspec-
tives piece describes critical flaws in Lichtenberg’s methods
and interpretation of his findings, including omission of key
confounding variables, the attribution of improved health
outcomes to newer drugs based on cross-sectional analysis
(where reverse causation is likely to explain much of the
observed effects), and unexplained observations that counter
well-established associations between socioeconomic status and
health outcomes. Baker and Fugh-Berman also note that
Lichtenberg’s approach fails to meet the rubric of common
clinicalsensebecauseheaggregatesawiderangeofdrugclasses,
from acne medications and proton pump inhibitors to cardiovas-
cular and HIV drugs, and examines their combined impact on
mortality. This one-size-fits-all analytic approach necessarily
ignores critical, disease-specific confounding factors.
Although Baker and Fugh-Berman’sc r i t i q u ei sn a r r o wi ni t s
scope-focusing on one study by a single investigator-it effectively
brings to light the major challenges for both pharmaceutical
policy and the care of patients: seeing clearly through the haze of
“facts” promoted by the industry and other vested interests that
are usedtoprotect drugprices,andidentifyingthe bestandmost
cost-effective therapies for medical conditions.
The debate on innovation, drug reimportation, cost of
developing new drugs, and whether other countries “are
paying for their fair share of innovation” are all centered on
the issue of how health care reform will impact drug prices, an
issue of critical concern to the pharmaceutical industry. This
type of policy research helps advance the case that any
reduction in drug prices will adversely impact innovation
and, consequently, our health. Lichtenberg’s work is important
to the industry because it helps advance the argument that
new drugs, while costly, are paying for themselves. He has
argued, for example, that the Veterans Administration formu-
lary has a detrimental effect on veteran life expectancy because
it restricts access to newer medications,
11 although published
data contradicts this claim and demonstrates that as a system
the VA delivers higher quality care compared to private plans
and has a lower mortality rate.
12–16 His work also helps thwart
policy proposals aimed at improving the affordability of
medications to public insurers or patients. Much of Lichten-
berg’s work, such as his VA formulary study, has been
disseminated through conservative, free-market oriented think
tanks like the Manhattan Institute, the Cato Institute, and the
American Enterprise Institute.
9,10,17 These entities are gener-
ally unreceptive to health care reform efforts that favor
expansion of public insurance programs. The interests of the
pharmaceutical industry and these think tanks tend to
coalesce around the notion of the importance of a free market
place for drugs and the detrimental effects of the monopsony
power of public programs on drug prices. Research that
supports the contention thatp u b l i ci n s u r a n c ep r o g r a m s
adversely impact health fit well with the conservative/libertar- Published online April 3, 2009
692ian agenda. This type of selective promotion of research, which
bypasses peer review, ignores conflicting research, and is used
to support ideological positions, is not exclusive to one side of
the ideological spectrum. However, given the resources of the
pharmaceutical industry and limited federal funding, pharma-
ceutical policy debates seem to be particularly dominated by
opinion, and non-peer reviewed and/or industry funded
research. In the early 1990s the Office of Technology and
Assessment was an important arbiter of fact versus fiction.
Today, no such congressional agency exists that can provide
unbiased filtered analysis to policymakers.
18
The larger national pharmaceutical policy debates not
withstanding, the challenge of disentangling the promotion of
ideology or marketing from research also has implications for
clinical practice. The last several years have witnessed several
insidious cases of drug promotion that even evaded the
scrutiny of reviewers and editors of major medical journals.
Ghostwriting scandals
19–21 plagued the VIGOR
22 and ADVAN-
TAGE
23 trials which understated the risks of rofecoxib, and
selective publishing of positive results may have led to over-
statements regarding the efficacy of selective serotonin-
reuptake inhibitors (SSRI)
24 where industry’s decision to
silence null studies distorted clinicians’ beliefs about the
efficacy of these commonly prescribed medications. The line
between research and marketing has been blurred to the point
that industry sponsored studies should be considered by
clinicians with a hefty grain of salt.
Unfortunately, as practicing physicians and clinical educa-
tors we face the twin problem of a dearth of unbiased
comparative effectiveness research and widespread dissemi-
nation of non-peer reviewed information about prescription
drugs. Rofecoxib was withdrawn from the market and rosigli-
tazone received a black box warning from the FDA, but only
after tens of millions of prescriptions were dispensed for both,
thanks to the generously-funded and aggressive advertising
campaigns of their manufacturers. Similarly, the use of
ezetimibe, a new and more expensive cholesterol reducing
medication, has grown to 15% of the cholesterol lowing drug
market in the US despite the availability of inexpensive generic
alternatives and lack of evidence of clinical superiority.
25,26 In
all these cases, a new drug was heavily promoted, side effects
understated or efficacy was overblown. Lichtenberg makes a
general claim that new drugs improve life expectancy, but
recent events suggest that new may not always be better.
Unfortunately for patients and providers, the slow pace of
science and/or lack of focused investment in comparative
effectiveness research usually means that as a society we pay
for expensive brand name medications more often than we
ought to, and often use them heavily only to later discover that
existing drugs are as effective and/or safer.
To ensure a more value-based approach to prescription drug
spending, unbiased information is needed both to address
basic comparative effectiveness questions and to inform
important policy debates. A number of researchers and health
care advocates have supported the development of a national
center for comparative effectiveness which would address the
dearth of good information on drugs.
27 Not surprisingly, while
the pharmaceutical industry is quick to claim that new drugs
save lives, they have not enthusiastically embraced the
development of such a national center. It is always easier to
claim improvements in health rather than prove them. How-
ever, in addition to the need for unbiased information on
drugs, policymakers also require unbiased policy analysis.
Otherwise, interested parties across the political spectrum can
find and selectively and aggressively disseminate research that
supports their positions. Absent serious public investment in
comparative effectiveness research and pharmaceutical policy
analysis disentangling fact versus fiction will continue to
remain a challenge both to clinicians and policymakers.
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